Hubertus von Baumbach | |
---|---|
Born | 1966 or 1967 (age 56–57)[1] |
Nationality | German |
Education | Massachusetts Institute of Technology |
Occupation | Businessman |
Title | Chairman and CEO, Boehringer Ingelheim |
Hubertus von Baumbach (born 1967) is a German businessman who is the chairman and CEO of Boehringer Ingelheim, Germany's second largest pharmaceutical company.[2]
The son of Erich von Baumbach and Ulrike Boehringer, Hubertus von Baumbach is also a great-grandson of the company's founder Albert Boehringer.[1] He has a law degree and an MBA from the Massachusetts Institute of Technology.[3][2]
Baumbach joined Boehringer Ingelheim in 2001.[3]
In November 2015, it was announced that Baumbach, who had been CFO, was appointed as chief executive, succeeding Andreas Barner in June 2016.[1][2] At the time, this made him the first member of the family at the helm in 25 years.[4] Within his first six months, he launched the biggest acquisition in the company's history (an asset swap deal with French rival Sanofi), followed by a reorganization to give the group a more decentralized divisional structure.[5]
In his capacity at Boehringer Ingelheim, Baumbach was part of Chancellor Angela Merkel’s delegation on three state visits to China.[6]